Key result
Preventing SERCA2 phosphorylation reduces myocardial infarct size ~34% versus wild-type controls in a mouse model.
Why the study?
Despite advances in cardioprotection, new therapeutic strategies capable of preventing ischemia-reperfusion injury in patients are still needed.
Preventing SERCA2 phosphorylation at serine 663 protects against ischemia-reperfusion injury by improving Ca2+ homeostasis, highlighting a potential therapeutic target for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Identifies SERCA2 Ser663 as a potential target to limit reperfusion injury; leaves open translation to human acute MI.
Despite advances in cardioprotection, new therapeutic strategies capable of preventing ischemia-reperfusion injury of patients are still needed. Here, we discover that sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase (SERCA2) phosphorylation at serine 663 is a clinical and pathophysiological event of cardiac function. Indeed, the phosphorylation level of SERCA2 at serine 663 is increased in ischemic hearts of patients and mouse. Analyses on different human cell lines indicate that preventing serine 663 phosphorylation significantly increases SERCA2 activity and protects against cell death, by counteracting cytosolic and mitochondrial Ca 2+ overload. By identifying the phosphorylation level of SERCA2 at serine 663 as an essential regulator of SERCA2 activity, Ca 2+ homeostasis and infarct size, these data contribute to a more comprehensive understanding of the excitation/contraction coupling of cardiomyocytes and establish the pathophysiological role and the therapeutic potential of SERCA2 modulation in acute myocardial infarction, based on the hotspot phosphorylation level of SERCA2 at serine 663 residue.
No takes yet. Share an insight, caveat, or question.
Gonnot et al. (2023) studied Ischemia-reperfusion injury. SERCA2 phosphoresistant mutant (S663A) vs. Wild-type SERCA2 was evaluated on Myocardial infarct size (% of area at risk). Preventing SERCA2 phosphorylation at serine 663 via a phosphoresistant mutant significantly reduced myocardial infarct size to 21.5% of the area at risk compared to 32.8% in wild-type controls in a mouse model of ischemia-reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: